Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

13D Filing: James E. Flynn and Proteon Therapeutics Inc (PRTO)

Page 1 of 17

Proteon Therapeutics Inc (NASDAQ:PRTO): James E. Flynn’s Deerfield Management filed an amended 13D.

You can check out Deerfield Management’s latest holdings and filings here.

Please follow Deerfield Management (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about Deerfield Management or update its stock holdings.

James E. Flynn
James E. Flynn
Deerfield Management

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Deerfield Special Situations Fund 0 149,676 0 149,676 149,676 0.85%
Deerfield Partners 0 197,424 0 197,424 197,424 1.12%
Deerfield International Master Fund 0 0 0 0 0 0.00%
Deerfield Private Design Fund III 0 877,799 0 877,799 877,799 4.98%
Deerfield Private Design Fund IV 0 16,082,018 0 16,082,018 16,082,018 9.985%
Deerfield Mgmt 0 347,100 0 347,100 347,100 1.97%
Deerfield Mgmt III 0 877,799 0 877,799 877,799 4.98%
Deerfield Mgmt IV 0 16,082,018 0 16,082,018 16,082,018 9.985%
Deerfield Management Company 0 17,306,917 0 17,306,917 17,306,917 9.985%
James E. Flynn 0 17,306,917 0 17,306,917 17,306,917 9.985%

Page 1 of 17 – SEC Filing

SECURITIES
AND EXCHANGE COMMISSION 

Washington,
D.C. 20549

SCHEDULE
13D

[Rule 13d-101]

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO §
24.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13D-2(a)

(Amendment No. 3)*

Proteon
Therapeutics, Inc.

(Name
of Issuer)

Common
Stock

(Title
of Class of Securities)

74371L109

(CUSIP
Number)

David Clark

Elliot Press

Deerfield Mgmt, L.P.

780 Third Avenue, 37th
Floor

New York, New York 10017

(212) 551-1600

With a copy to:

Mark D. Wood, Esq.

Jonathan D. Weiner, Esq.

Katten Muchin Rosenman LLP

575 Madison Avenue

New York, New York 10022

(212) 940-8800

(Name,
Address and Telephone Number of Person Authorized to Receive Notices and Communications)

November
30, 2017

(Date
of Event which Requires Filing of this Statement)

If the filing person
has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing
this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ☐.

Note: Schedules
filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7
for other parties to whom copies are to be sent.

(Continued on following
pages)

(Page 1 of 17 Pages)

* The remainder of this cover page shall be filled out for a
reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment
containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page
shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”)
or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however,
see the Notes).

Follow Proteon Therapeutics Inc (NASDAQ:PRTO)
Trade (NASDAQ:PRTO) Now!
Page 1 of 17
Loading...